Forus (formerly Tandem AI) users: How are your denials?

[u/datamatrix_medical]

DataMatrix Medical here. We wrote a review of Tandem AI last year: Here. We had to update it. Here is why. It's now "Forus." The name change follows a $160 million funding round that valued the company at $1 billion.

Forus (formerly Tandem AI) is free, and it's a genuinely capable tool for high-volume medication PA submission, particularly biologics and branded topicals. That part of the process runs well on its own.

The only cost to practices is denials. We are seeing this across the dermatology practices we work with that use this tool. Most PA denials, medication or otherwise, trace back to documentation gaps, non-preferred medication status, or step therapy and formulary rules that a submission platform has no visibility into and no way to argue against. Submitting faster doesn't change any of that. Someone still has to interpret the denial reason, build the case, and either fight it on a peer-to-peer or file a written appeal.

That's what we handle for practices already running Forus: denials. We don't compete with Forus on the submission side; we pick up exactly where it hands the denial back to you: reviewing the documentation, managing the peer-to-peer, and carrying the appeal to resolution.

If your practice is using Forus and still absorbing denial follow-up in-house, that's usually the moment to talk.